Vertex Pharmaceuticals Inc / MA financial statements, FY2008–FY2025
Vertex Pharmaceuticals Inc / MA reported revenue of $12B and net income of $3.95B for the fiscal year ended 2025-12-31, as stated in its filing with US SEC EDGAR. Listed as VRTX (Nasdaq). Fiscal year ends 31 December.
FactReportedAnnual figures as reported, in USD, 6 measures over 20 fiscal years. Each value links to the filing it came from. Nothing is restated, annualised, converted or estimated; a period a filing did not state is shown as a gap.
Annual results by fiscal year
| Fiscal year end | Revenue | Operating income | Net income | Total assets | Total liabilities | Stockholders' equity |
|---|---|---|---|---|---|---|
| 2025-12-31 | $12B | $4.17B | $3.95B | $25.6B | $6.98B | $18.7B |
| 2024-12-31 | $11B | -$233M | -$536M | $22.5B | $6.12B | $16.4B |
| 2023-12-31 | $9.87B | $3.83B | $3.62B | $22.7B | $5.15B | $17.6B |
| 2022-12-31 | $8.93B | $4.31B | $3.32B | $18.2B | $4.24B | $13.9B |
| 2021-12-31 | $7.57B | $2.78B | $2.34B | $13.4B | $3.33B | $10.1B |
| 2020-12-31 | $6.21B | $2.86B | $2.71B | $11.8B | $3.06B | $8.69B |
| 2019-12-31 | $4.16B | $1.2B | $1.18B | $8.32B | $2.23B | $6.09B |
| 2019-01-01 | — | — | — | $6.26B | — | — |
| 2018-12-31 | $3.05B | $635M | $2.1B | $6.25B | $1.81B | $4.44B |
| 2018-01-01 | — | — | — | $3.56B | — | — |
| 2017-12-31 | $2.49B | $123M | $263M | $3.55B | $1.5B | $2.03B |
| 2016-12-31 | $1.7B | $9.94M | -$112M | $2.9B | $1.56B | $1.16B |
| 2015-12-31 | $1.03B | -$467M | -$556M | $2.5B | $1.4B | $940M |
| 2014-12-31 | $580M | -$692M | -$739M | $2.33B | $1.24B | $1.08B |
| 2013-12-31 | $1.21B | -$610M | -$445M | $2.32B | $963M | $1.36B |
| 2012-12-31 | $1.53B | $46.7M | -$107M | $2.76B | $1.52B | $999M |
| 2011-12-31 | $1.41B | $114M | $29.6M | $2.2B | $1.24B | $787M |
| 2010-12-31 | $143M | -$696M | -$755M | $1.73B | $1.22B | $504M |
| 2009-12-31 | $102M | -$614M | -$642M | $1.96B | $859M | — |
| 2008-12-31 | $176M | -$463M | — | — | — | — |
About these figures
Every number on this page is a fact with a filing behind it, retrieved from US SEC EDGAR and stored with the period it belongs to. Figures are shown as the company reported them for that period; a later restatement supersedes the earlier value rather than overwriting it. Market capitalisation is not shown anywhere on this site because no licensed price source is used; the profile shows reported public float where a filing states it.